How can phase-appropriate GMPs transform CDMO partnerships?

Rui Teixeira, CDMO director, Suanfarma explores how phase-appropriate GMPs can transform CDMO partnerships.

In today’s CDMO market, the real differentiator is not only capacity or compliance, but also the ability to apply compliance intelligently, accelerating innovation without compromising quality. This is where applying phase-appropriate GMP’s becomes a strategic enabler. 

New medicines development is defined by a delicate balance: the need to move fast, the pressure to contain costs, and the obligation to safeguard patient safety. Traditional one-size-fits-all Quality…